Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

BACKGROUND: Novel immunotherapies, or checkpoint inhibitors, targeting programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have significantly improved outcomes for patients with numerous different cancer types. However, owing to their exclusion from clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, Marc, Trinh, Van A., Haymaker, Cara, Jackson, Natalie, Kim, Dae Won, Allison, James P., Sharma, Padmanee, Vence, Luis, Bernatchez, Chantale, Hwu, Patrick, Diab, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011857/
https://www.ncbi.nlm.nih.gov/pubmed/27595932
http://dx.doi.org/10.1186/s13045-016-0309-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011857/
https://www.ncbi.nlm.nih.gov/pubmed/27595932
http://dx.doi.org/10.1186/s13045-016-0309-7

Ejemplares similares